1. [CASE 1 — QUESTION 1] R.T. is a 62-year-old man with hypertension referred for resistant hypertension. He is on lisinopril 40 mg, amlodipine 10 mg, and chlorthalidone 25 mg daily. His home BP average is 164/98 mmHg. He reports full adherence. His physician arranges ABPM (confirms persistent hypertension), urine drug levels (confirms adherence), and a secondary cause workup. Results: PRA 0.3 ng/mL/hr (suppressed); aldosterone-to-renin ratio 24; potassium 3.9 mEq/L; eGFR 64 mL/min/1.73m2; normal cortisol, TSH, renal artery duplex, and polysomnography. Which of the following most accurately identifies the dominant pathophysiological mechanism driving R.T.'s resistant hypertension and the pharmacological rationale for the next intervention?

• A) The suppressed PRA indicates bilateral renal artery stenosis causing ischemic renin suppression — the renovascular hypertension is driving resistance; renal artery angioplasty is the treatment of choice before any further pharmacological intervention
• B) The suppressed PRA indicates low sympathetic tone hypertension — a centrally acting agent (clonidine 0.1 mg twice daily) is pharmacologically appropriate to address the central component of hypertension not captured by peripheral RAAS inhibition
• C) The ARR of 24 confirms primary aldosteronism requiring adrenal CT and adrenal vein sampling before any pharmacological change — spironolactone cannot be initiated until the lateralization of aldosterone excess is determined
• D) The PRA and ARR values are within normal ranges; the resistant hypertension is essential in nature with no identifiable pharmacological target; the only remaining option is referral for renal denervation
• E) The suppressed PRA (0.3 ng/mL/hr) and borderline-elevated ARR (24) indicate volume-dependent, subclinical aldosterone-mediated physiology — the physiological profile most strongly predicting spironolactone response in PATHWAY-2; the ARR of 24 does not meet the formal diagnostic threshold for primary aldosteronism (typically ≥20–30 with confirmatory testing), but PATHWAY-2 demonstrated spironolactone is the most effective fourth-line agent in resistant hypertension regardless of whether formal primary aldosteronism criteria are met; the low PRA predicts the greatest magnitude of response; spironolactone 25 mg daily should be initiated with potassium and creatinine recheck at 2 weeks

2. [CASE 1 — QUESTION 2] Spironolactone 25 mg daily is added. At 6 weeks, R.T.'s home BP is 136/84 mmHg — at target. Potassium is 4.6 mEq/L and creatinine is 1.2 mg/dL (unchanged from baseline). He is tolerating the regimen well. His physician plans long-term monitoring. At his 6-month review, R.T. reports mild gynecomastia (tender breast tissue bilaterally) that started about 2 months ago. He is distressed and requests a change. His physician considers switching spironolactone to eplerenone. Which of the following most accurately describes the pharmacological basis for the gynecomastia and the practical considerations when switching to eplerenone?

• A) The gynecomastia is caused by spironolactone activating estrogen receptors in breast tissue directly — eplerenone avoids this because it does not enter breast tissue due to its lower lipophilicity; the switch will eliminate the gynecomastia without any dose or frequency adjustments needed
• B) The gynecomastia indicates that spironolactone has been producing excessive aldosterone blockade — the anti-androgenic effects are a marker of over-treatment; the dose should be reduced to 12.5 mg rather than switching to eplerenone
• C) Spironolactone's steroidal structure allows binding to androgen and progesterone receptors in addition to the mineralocorticoid receptor — this off-target receptor binding reduces androgenic tone in breast tissue relative to estrogen, causing gynecomastia and mastalgia; eplerenone is a selective MRA with minimal affinity for sex hormone receptors, eliminating this off-target effect; however, eplerenone is approximately 60% as potent per mg as spironolactone and requires twice-daily dosing for equivalent MR blockade duration — switching from spironolactone 25 mg once daily to eplerenone 25–50 mg twice daily is the appropriate substitution; BP and potassium should be reassessed 4–6 weeks after switching as some patients experience modest BP increase due to eplerenone's lower MR potency
• D) The gynecomastia is caused by chlorthalidone impairing testosterone synthesis — switching the diuretic from chlorthalidone to torsemide will resolve the gynecomastia without requiring any change to spironolactone
• E) The gynecomastia is an expected and unavoidable consequence of achieving BP control in resistant hypertension — all effective fourth-line agents including eplerenone cause gynecomastia through the same mechanism; the patient should be counseled to accept it as a necessary treatment adverse effect

3. [CASE 1 — QUESTION 3] Spironolactone is switched to eplerenone 25 mg twice daily. At 6 weeks, BP is 140/88 mmHg — slightly above target (the modest BP increase predicted with the switch). Gynecomastia has resolved. Potassium is 4.8 mEq/L. The physician considers uptitrating eplerenone to 50 mg twice daily. Which of the following most accurately identifies the pharmacological considerations for eplerenone uptitration and the expected outcome?

• A) Uptitrating eplerenone from 25 mg to 50 mg twice daily is pharmacologically appropriate — eplerenone's dose-response relationship is steep enough that doubling the dose substantially increases MR receptor occupancy and should provide additional BP reduction of approximately 3–5 mmHg systolic; potassium must be rechecked within 2 weeks of uptitration given the increased MR blockade at higher doses and the existing background of lisinopril (which conserves potassium); if potassium remains below 5.5 mEq/L, the higher dose can be continued; the target dose in outcome trials such as EMPHASIS-HF was eplerenone 50 mg daily (not twice daily), but for hypertension the twice-daily 50 mg regimen may be needed for adequate 24-hour coverage given eplerenone's shorter half-life relative to spironolactone
• B) Eplerenone cannot be uptitrated beyond 25 mg twice daily — the maximum approved dose for hypertension is 25 mg twice daily; 50 mg twice daily is only approved for heart failure and would constitute off-label use contraindicated in a patient without HFrEF
• C) Eplerenone uptitration is not needed — the slightly elevated BP of 140/88 mmHg is within acceptable range for a 62-year-old man; a target of below 140/90 mmHg by older guideline standards has been achieved and no further medication change is required
• D) Before uptitrating eplerenone, lisinopril should be reduced to 20 mg — the combination of higher-dose eplerenone with full-dose ACEi at eGFR 64 always requires ACEi dose reduction to prevent AKI; this is a mandatory safety step before any eplerenone dose increase
• E) Eplerenone should be switched back to spironolactone 25 mg at this point — the loss of BP control with eplerenone confirms that spironolactone's greater MR potency was required for adequate control; the gynecomastia should be managed with topical testosterone gel to restore the androgen balance rather than changing the antihypertensive

4. [CASE 1 — QUESTION 4] Eplerenone is uptitrated to 50 mg twice daily. At 8 weeks, BP is 132/82 mmHg — at target. Potassium is 5.1 mEq/L (borderline). Creatinine is stable. R.T. is now on five agents: lisinopril 40 mg, amlodipine 10 mg, chlorthalidone 25 mg, and eplerenone 50 mg twice daily — and is well controlled. At his 12-month review, R.T. asks about renal denervation, which he read about online. He asks whether it could replace any of his medications. Which of the following most accurately describes the appropriate counseling regarding renal denervation in this patient's clinical context?

• A) Renal denervation is the treatment of choice at this stage — R.T. has confirmed resistant hypertension and has been on four-drug therapy for over a year; guideline pathways indicate that device therapy should replace pharmacotherapy after 12 months of drug failure; he should be referred immediately
• B) Renal denervation is contraindicated in patients on MRAs — the aldosterone-mediated sodium retention that MRAs address is the physiological substrate that renal denervation targets; combining the two would cause excessive natriuresis and hypotension; he must choose one or the other
• C) Renal denervation is a curative procedure — it permanently eliminates the sympathetic drive to hypertension; after successful RDN, all antihypertensive medications can be discontinued within 6 months of the procedure; it is appropriate to refer R.T. for RDN with the intent of medication elimination
• D) Renal denervation received FDA approval in 2023 as an adjunct — not a replacement — for antihypertensive therapy in resistant hypertension; evidence from SPYRAL HTN-ON MED and RADIANCE-HTN TRIO demonstrated BP reduction versus sham on background pharmacotherapy; R.T.'s BP is now at target on pharmacological optimization; RDN should be considered only if pharmacological therapy becomes inadequate or causes intolerable adverse effects; it does not replace medications and patients typically continue their antihypertensive regimen after RDN; the most appropriate response is to explain this evidence-based context, acknowledge his interest, and indicate that RDN can be revisited if future control becomes inadequate or if adverse effect burden becomes unacceptable
• E) Renal denervation has not received regulatory approval anywhere in the world — SYMPLICITY HTN-3 definitively showed it was no more effective than sham; the patient should be told it is an experimental procedure with no proven benefit and no role in clinical practice

5. [CASE 2 — QUESTION 5] S.K. is a 58-year-old woman with hypertension and type 2 diabetes who presents to the emergency department. Her husband called 911 after finding her confused at home. On arrival, BP is 226/134 mmHg, heart rate 96 bpm. She is confused, with bilateral papilledema on fundoscopy. Urinalysis shows 3+ proteinuria. Troponin is mildly elevated (0.08 ng/mL, upper limit of normal 0.04 ng/mL). ECG shows LVH with strain pattern but no ST-segment elevation or depression. Creatinine is 2.4 mg/dL (baseline 1.1 mg/dL from records). She has no history of coronary artery disease. Which of the following most accurately identifies the clinical syndrome, the most pressing management priorities, and the initial pharmacological approach?

• A) This is hypertensive urgency — BP above 180/120 mmHg without confirmed end-organ damage does not qualify as emergency; the mild troponin elevation is non-specific and the papilledema may be chronic; oral antihypertensives should be given and the patient discharged with 48-hour follow-up
• B) This is hypertensive emergency with multiple acute target organ damage manifestations: hypertensive encephalopathy (confusion, papilledema), acute hypertensive nephropathy (creatinine rising from 1.1 to 2.4 mg/dL — a 118% increase acutely), and cardiac stress (mildly elevated troponin, LVH with strain); the management priority is immediate admission to a monitored setting, IV antihypertensive therapy targeting MAP reduction of no more than 25% in the first hour, then gradual reduction over 24–48 hours; IV nicardipine or labetalol are appropriate initial agents; the troponin elevation requires serial measurement to exclude concurrent ACS, though the pattern (mildly elevated, no ischemic ECG changes, LVH with strain — known to cause demand-related troponin elevation) is most consistent with hypertensive demand ischemia rather than coronary occlusion
• C) This is hypertensive emergency but the acute kidney injury is the primary concern — IV furosemide 80 mg should be the first agent initiated to address the volume overload driving the AKI; BP reduction should be deferred until the creatinine begins to improve
• D) This is STEMI equivalent — the troponin elevation in the setting of severely elevated BP requires emergent catheterization regardless of ECG findings; antihypertensive therapy should be deferred until after coronary angiography to avoid reducing coronary perfusion pressure before any culprit lesion is identified
• E) This is hypertensive encephalopathy only — the troponin elevation and creatinine rise are incidental and do not represent acute target organ damage; only the neurological manifestations require treatment; BP should be reduced slowly over 72 hours using oral agents

6. [CASE 2 — QUESTION 6] S.K. is admitted to the ICU. IV nicardipine infusion is initiated and titrated. Over the first hour, MAP is reduced by 23% — within the 25% target. Her BP is now 178/108 mmHg and she is alert and oriented. The nicardipine infusion continues to gradually reduce BP. Over the next 5 hours, BP reaches 162/100 mmHg. Troponin peaks at 0.14 ng/mL at 6 hours and begins declining at 12 hours. Creatinine stabilizes at 2.1 mg/dL and begins falling. The intensivist plans to transition from IV nicardipine to oral antihypertensives. Which of the following most accurately identifies the transition strategy and the rationale?

• A) Transition to oral nifedipine immediate-release 10 mg — IV to oral transition in hypertensive emergency always uses the short-acting formulation of the same drug class to provide overlap coverage during the switchover; nifedipine IR is safe and effective for this transition
• B) Transition to IV esmolol infusion before oral agents — once hemodynamic stabilization is achieved with a CCB, beta-blockade should be established to prevent rebound tachycardia during the transition off the IV CCB; esmolol provides a safe bridge
• C) Discharge immediately with oral amlodipine 10 mg once BP is below 160/100 mmHg — inpatient management is no longer necessary once BP has responded to IV therapy; same-day discharge with close follow-up is the standard approach
• D) Transition to oral nicardipine 20 mg three times daily as the first step — using the oral formulation of the same agent provides pharmacological continuity and prevents any gap in drug effect during IV discontinuation
• E) Begin oral antihypertensives while the nicardipine infusion is still running at a low rate, then taper and discontinue the infusion as oral agents reach steady state; appropriate oral agents for this patient (hypertension with type 2 diabetes and now significant proteinuria from the hypertensive AKI) include an ACEi or ARB (amlodipine/ACEi combination preferred given ACCOMPLISH evidence and the new proteinuric CKD), with chlorthalidone as a third agent; nifedipine IR is specifically contraindicated for IV-to-oral transition due to its unpredictable rapid BP drops; oral CCBs for chronic use should be long-acting formulations only

7. [CASE 2 — QUESTION 7] S.K. is discharged on day 4 on ramipril 5 mg, amlodipine 5 mg, and chlorthalidone 12.5 mg daily — all at starting doses to allow careful uptitration given the recent AKI. Her creatinine at discharge is 1.6 mg/dL (still above her baseline of 1.1 mg/dL but improving). BP at discharge is 148/92 mmHg. She is asked to follow up with her primary care physician in 1 week. At the 1-week visit, BP is 144/90 mmHg. Creatinine is 1.3 mg/dL (continuing to improve). Potassium is 4.4 mEq/L. Her physician wants to optimize her regimen more aggressively given her diabetes, proteinuria, and recent hypertensive emergency. Which of the following most accurately identifies the optimization priority and the pharmacological rationale?

• A) Increase chlorthalidone to 25 mg immediately — volume reduction is the most important priority in a patient with recent hypertensive emergency; maximizing diuresis before optimizing RAAS inhibition prevents recurrence of the volume-driven hypertension that precipitated the emergency
• B) Switch ramipril to an ARB — ARBs are more effective than ACEi at reducing proteinuria in diabetic nephropathy because they have higher AT1 receptor affinity; RENAAL demonstrated ARB superiority over ACEi for renoprotection in type 2 diabetic nephropathy
• C) Add a beta-blocker as the fourth agent — beta-blockers are the most important addition in a post-hypertensive emergency patient because sympathetic activation is the primary recurrence driver; bisoprolol 5 mg should be added before any other changes
• D) Uptitrate ramipril toward the maximum dose (10 mg daily) as the first optimization step — the RAAS inhibitor is the pharmacological cornerstone for this patient with type 2 diabetes and proteinuric CKD (UACR will need to be quantified but the 3+ proteinuria at presentation confirms significant proteinuria); maximizing RAAS inhibition provides both antihypertensive and nephroprotective benefit through reduced intraglomerular pressure; the creatinine is improving and potassium is 4.4 mEq/L — both support safe uptitration; amlodipine and chlorthalidone can be uptitrated subsequently as needed
• E) Maintain all current doses unchanged for 3 months — the recent AKI from the hypertensive emergency contraindicates any medication changes for at least 90 days; stability of the regimen is the priority over optimization

8. [CASE 2 — QUESTION 8] Three months later, S.K. is on ramipril 10 mg, amlodipine 10 mg, and chlorthalidone 25 mg daily. BP is 134/82 mmHg — at target. Creatinine has returned to 1.2 mg/dL (close to her baseline of 1.1 mg/dL). UACR is 380 mg/g. Potassium is 4.1 mEq/L. Her endocrinologist has recently started empagliflozin 10 mg daily for her type 2 diabetes. Her physician reviews the addition for any antihypertensive interactions or implications. Which of the following most accurately evaluates the pharmacological implications of adding empagliflozin to her current antihypertensive regimen?

• A) Empagliflozin's SGLT2 inhibition produces osmotic diuresis through glycosuria (reducing tubular glucose reabsorption) and natriuresis (through NHE3 inhibitor-like effects on the proximal tubule), providing modest additional BP reduction of approximately 3–5 mmHg systolic and 2 mmHg diastolic — complementary to her existing three-drug antihypertensive regimen; additionally, empagliflozin has demonstrated cardiovascular and renal protective effects (EMPA-REG OUTCOME, CREDENCE-extended class evidence) specifically in patients with diabetic CKD and proteinuria — making it an evidence-based addition beyond its antihypertensive contribution; the volume-depleting effect may necessitate monitoring for orthostatic hypotension given the background chlorthalidone, and she should be counseled about adequate hydration; no dose adjustment of her antihypertensives is required at initiation, but BP should be monitored at 4 weeks
• B) Empagliflozin is contraindicated with chlorthalidone — both agents cause natriuresis through different mechanisms and their combination causes additive electrolyte disturbances including severe hyponatremia; chlorthalidone must be discontinued before empagliflozin is started
• C) Empagliflozin raises BP through SGLT2-mediated sodium retention — blocking glucose reabsorption at SGLT2 stimulates compensatory upregulation of NHE3 in the proximal tubule, causing sodium retention that counteracts the antihypertensive regimen; her BP should be rechecked in 2 weeks and the chlorthalidone dose increased preemptively
• D) Empagliflozin interacts with ramipril through ACE2 receptor upregulation — SGLT2 inhibitors upregulate ACE2 expression in the kidney, which cleaves angiotensin II to angiotensin 1-7; the combination with ramipril causes excessive RAAS suppression producing dangerous hypotension; ramipril should be reduced to 5 mg before empagliflozin is initiated
• E) Empagliflozin has no antihypertensive properties and no interactions with her current regimen — it is a purely glucose-lowering agent and does not affect BP, fluid balance, or the pharmacological mechanisms of any existing antihypertensive; her regimen can continue unchanged without any additional monitoring

9. [CASE 3 — QUESTION 9] T.M. is a 45-year-old man with no prior medical history who presents for a new patient visit. BP is 162/98 mmHg on two separate readings taken 5 minutes apart. He has no symptoms. BMI is 29 kg/m2. He has a 15 pack-year smoking history (quit 3 years ago) and a family history of MI in his father at age 52. His 10-year ASCVD risk is calculated at 12%. Labs: fasting glucose 98 mg/dL, total cholesterol 218 mg/dL, HDL 42 mg/dL, LDL 148 mg/dL, creatinine 0.9 mg/dL, potassium 4.1 mEq/L. He has never been on antihypertensives. He is motivated and asks about starting medication. Which of the following most accurately identifies the initial treatment strategy?

• A) Lifestyle modification alone for 6 months — T.M. has Stage 2 hypertension but his ASCVD risk of 12% places him in the moderate-risk category where lifestyle modification should be attempted before pharmacotherapy; this is consistent with JNC 7 recommendations for non-urgent hypertension
• B) Initiate monotherapy with chlorthalidone 12.5 mg — ALLHAT established chlorthalidone as the most effective single agent for all-cause cardiovascular prevention; in a 45-year-old man with stage 2 hypertension and moderate cardiovascular risk, chlorthalidone monotherapy followed by sequential addition is the evidence-supported approach
• C) Initiate dual combination therapy with a RAAS inhibitor plus CCB (lisinopril 5 mg plus amlodipine 5 mg, or a single-pill combination) alongside lifestyle modification — T.M. has Stage 2 hypertension (BP 162/98 mmHg, which is 32/18 mmHg above his target of 130/80 mmHg given his ASCVD risk of 12%) and high cardiovascular risk (ASCVD ≥10%); ACC/AHA 2017 recommends pharmacotherapy for Stage 1 hypertension with ASCVD ≥10% and for all Stage 2 hypertension; the 32-mmHg systolic distance from target makes dual therapy appropriate from initiation; the RAAS inhibitor plus CCB combination is the preferred dual regimen (ACCOMPLISH evidence); starting at reduced doses of each agent provides equivalent BP reduction to full-dose monotherapy with fewer adverse effects
• D) Initiate statin therapy as the first intervention — T.M.'s LDL of 148 mg/dL with an ASCVD risk of 12% meets the threshold for statin initiation; cardiovascular risk reduction through lipid lowering is more effective than BP reduction at this BP level in a patient with Stage 2 hypertension
• E) Refer to cardiology before initiating antihypertensive therapy — a 45-year-old man with Stage 2 hypertension and an ASCVD risk of 12% requires specialist evaluation before primary care antihypertensive initiation; this case complexity exceeds primary care scope

10. [CASE 3 — QUESTION 10] T.M. is started on lisinopril 5 mg plus amlodipine 5 mg daily, plus rosuvastatin 10 mg and aspirin 81 mg. At 6 weeks, BP is 144/90 mmHg — improved but above target. Both antihypertensives are uptitrated to their maximum doses (lisinopril 40 mg, amlodipine 10 mg). At 12 weeks, BP is 134/84 mmHg — at target. Potassium is 4.2 mEq/L. Creatinine is stable. T.M. now asks whether the aspirin is necessary. His physician reviews the current evidence for aspirin in primary prevention. Which of the following most accurately reflects the current evidence-based approach to aspirin in primary cardiovascular prevention for a patient like T.M.?

• A) Aspirin for primary prevention in T.M. is not recommended by current ACC/AHA 2019 guidelines for most patients without established CVD — the balance of evidence shows that the risk of major bleeding (GI hemorrhage, intracranial hemorrhage) from routine aspirin in the primary prevention setting equals or exceeds the benefit of cardiovascular event reduction; the 2018 ASPREE trial (elderly adults without prior CVD), ARRIVE trial (moderate-risk individuals), and ASCEND trial (diabetic patients without established CVD) all demonstrated no net benefit or harm from aspirin in primary prevention populations; ACC/AHA 2019 guidelines reserve aspirin for secondary prevention (established CVD) or selected high-risk patients with low bleeding risk at age 40–70; T.M. at age 45 with no established CVD and moderate bleeding risk is not clearly in the group where benefit exceeds risk; his aspirin should be reconsidered
• B) Aspirin 81 mg daily is mandatory for all patients with ASCVD risk above 10% regardless of age — T.M.'s 12% ASCVD risk firmly places him in the guideline-mandated aspirin category; stopping it would be harmful
• C) Aspirin should be increased to 325 mg daily for T.M. — low-dose aspirin 81 mg is insufficient for primary prevention in a patient with Stage 2 hypertension; higher doses provide more complete COX-1 inhibition and greater platelet aggregation prevention in hypertensive patients
• D) Aspirin should be continued indefinitely — once started, aspirin discontinuation in a primary prevention patient causes rebound platelet hyperactivation that substantially increases MI risk above baseline; stopping aspirin is more dangerous than continuing it
• E) Aspirin 81 mg should be continued because T.M.'s ASCVD risk of 12% places him in the high-risk category where the number needed to treat to prevent one MI is small enough to clearly outweigh the bleeding risk; current guidelines universally recommend aspirin in all high-risk primary prevention patients

11. [CASE 3 — QUESTION 11] Aspirin is discontinued after shared decision-making discussion. T.M. continues lisinopril 40 mg, amlodipine 10 mg, and rosuvastatin 10 mg. His BP remains at target (132/82 mmHg) at 6-month follow-up. He asks about home blood pressure monitoring and whether he still needs to come in for office visits. He reports his home readings over the past month have averaged 128/80 mmHg. Which of the following most accurately describes the role of home blood pressure monitoring and office visits in his ongoing care?

• A) Home BP monitoring is not reliable — automated home devices have not been validated against invasive arterial measurement in primary prevention populations; all BP monitoring should occur in the office to ensure accuracy and appropriate clinical context
• B) Home BP monitoring should replace office visits entirely — T.M. is at target; office visits are only needed when BP rises above 140/90 mmHg; he can self-monitor and contact the office remotely if readings consistently exceed this threshold
• C) His home readings of 128/80 mmHg confirm white coat hypertension — his office readings are consistently higher than home readings, proving that office measurement overestimates his true BP; his antihypertensives should be reduced
• D) Home BP monitoring is unreliable in patients on amlodipine because CCBs cause peripheral edema that distorts cuff-based measurements at the arm; wrist monitors should be used instead
• E) Home BP monitoring is valuable and guideline-endorsed for most hypertensive patients — it improves treatment decisions by revealing the true out-of-office BP burden, detects white coat and masked hypertension, improves patient engagement and adherence, and provides a larger dataset for clinical decision-making than infrequent office visits; T.M.'s home average of 128/80 mmHg confirms good ambulatory BP control and is reassuring; office visits should continue at a reduced but regular frequency (every 3–6 months once stably controlled) for medication review, laboratory monitoring (potassium, creatinine, lipids), adherence assessment, and cardiovascular risk factor management — home monitoring complements but does not replace clinical follow-up

12. [CASE 3 — QUESTION 12] T.M. is followed for 2 years with excellent BP control (home average consistently 126–132/78–82 mmHg) on lisinopril 40 mg and amlodipine 10 mg. He develops mild peripheral edema (1+ bilateral ankle edema) that has been present for the past 3 months. He reports it is not painful but cosmetically bothersome. BNP is normal. There is no orthopnea or exertional dyspnea. ECG and echocardiogram (ordered to exclude cardiac cause) show only mild LVH — no HFrEF. Which of the following most accurately identifies the mechanism of the edema and the pharmacological options?

• A) The edema is caused by lisinopril-mediated aldosterone escape — after 2 years of ACEi therapy, aldosterone secretion escapes from suppression and causes sodium retention; the solution is to switch lisinopril to an ARB, which provides more complete and sustained aldosterone suppression
• B) The edema is amlodipine-associated CCB peripheral edema — caused by preferential arteriolar dilation without matched venodilation, raising capillary hydrostatic pressure in dependent tissues; management options include: (1) adding a RAAS inhibitor uptitration approach — lisinopril is already at maximum dose; (2) switching amlodipine to felodipine, which has higher vascular selectivity and produces less peripheral edema at equivalent antihypertensive doses; (3) reducing amlodipine dose (5 mg) accepting some loss of BP control; (4) adding a low-dose thiazide diuretic (chlorthalidone 12.5 mg) to counteract the edema while also completing the standard triple combination — this last option both addresses the edema through volume reduction and strengthens the antihypertensive regimen; given T.M.'s BP is at target, switching to felodipine is the most pharmacologically targeted option that maintains BP control without adding a new drug class
• C) The edema is caused by lisinopril-induced bradykinin accumulation in peripheral vessels — the same mechanism causing the cough also increases vascular permeability in limb vessels; switching to an ARB will eliminate both the edema and any residual cough
• D) The edema requires cardiac investigation before any pharmacological change — mild LVH on echo, even without HFrEF, indicates pre-clinical heart failure; diuretic therapy is mandatory before any CCB modification can be considered safely
• E) The edema is benign and pharmacologically unavoidable in any patient on long-term antihypertensive therapy — all antihypertensive drug classes cause peripheral edema through different mechanisms; no pharmacological modification is needed and the patient should be counseled to elevate his legs at rest

13. [CASE 4 — QUESTION 13] U.P. is a 77-year-old woman with isolated systolic hypertension (ISH) — BP consistently 172/64 mmHg on home monitoring. She has no history of coronary artery disease, heart failure, diabetes, or CKD. She lives alone and is functionally independent. She has never been on antihypertensives. Her physician plans to initiate pharmacological treatment. Which of the following most accurately describes the pharmacological approach appropriate for U.P., including agent selection and titration strategy?

• A) No pharmacological treatment is indicated — U.P. has a diastolic BP of 64 mmHg, which is below the 70 mmHg J-curve threshold; initiating antihypertensives will further reduce diastolic BP and cause coronary hypoperfusion; lifestyle modification is the only safe intervention for ISH with low diastolic BP
• B) Initiate IV labetalol for the initial dose — beta-blockade is the most effective initial antihypertensive for ISH because elevated pulse pressure in the elderly reflects sympathetic-driven tachycardia; IV initiation allows precise dose titration before transitioning to oral therapy
• C) Initiate ramipril 2.5 mg daily — RAAS inhibitors are the preferred initial agent for elderly women because their reduction of angiotensin II-mediated arterial stiffness directly addresses the pathophysiology of ISH; evidence from HOPE specifically supports ramipril in elderly patients with isolated systolic hypertension
• D) Initiate amlodipine 2.5 mg daily (or chlorthalidone/indapamide at low dose) with a "start low, go slow" titration strategy — elderly patients with ISH respond well to DHP CCBs and thiazide-type diuretics based on ALLHAT (chlorthalidone), SHEP (chlorthalidone), SYST-EUR (nitrendipine — a DHP CCB), and HYVET (indapamide) evidence; beta-blockers are less effective for ISH and are not the preferred initial agent; ACEi and ARBs are less effective as monotherapy in elderly low-renin patients but are appropriate with compelling indications; U.P.'s diastolic BP of 64 mmHg warrants caution — very low diastolic pressure could exacerbate J-curve risk if systolic target is pursued aggressively; the "start low, go slow" principle applies: begin at the lowest available dose and titrate slowly over weeks to months, monitoring for orthostatic hypotension and falls at every visit
• E) Initiate metoprolol succinate 25 mg daily — ISH is driven by reduced aortic compliance and elevated sympathetic output; beta-blockade addresses both by reducing cardiac output and blunting the adrenergic component of elevated systolic pressure; SHEP demonstrated beta-blocker superiority for ISH

14. [CASE 4 — QUESTION 14] Amlodipine 2.5 mg daily is initiated. At 6 weeks, BP is 158/62 mmHg — systolic improved by 14 mmHg but still above target. Diastolic is now 62 mmHg (slightly lower). The physician wants to uptitrate amlodipine to 5 mg. U.P. reports she feels slightly dizzy when getting up from her chair quickly. BP lying is 158/62 mmHg; BP standing at 1 minute is 142/56 mmHg (16 mmHg systolic drop). She has not fallen. Which of the following most accurately identifies the significance of this finding and the appropriate management?

• A) The orthostatic drop of 16 mmHg systolic is clinically insignificant — significant orthostatic hypotension requires a drop of at least 30 mmHg systolic; the amlodipine dose should be uptitrated to 5 mg as planned; the dizziness is positional anxiety in an elderly patient, not pharmacological
• B) The orthostatic drop of 16 mmHg systolic meets the clinical definition of orthostatic hypotension (defined as a drop of ≥20 mmHg systolic or ≥10 mmHg diastolic within 3 minutes of standing) — the 16 mmHg systolic drop is borderline below the 20 mmHg threshold but is symptomatic (dizziness on standing), which elevates its clinical significance; uptitrating amlodipine may worsen orthostatic hypotension further by increasing peripheral vasodilation; the appropriate response is to address the orthostatic symptoms first — counsel on slow position changes (sitting at the edge of the chair for 30 seconds before standing, rising slowly), ensure adequate hydration, review for other contributing medications; recheck orthostatic measurements in 2 weeks before deciding on dose uptitration; if symptoms resolve, uptitration to 5 mg can proceed cautiously
• C) Orthostatic hypotension in an elderly patient on amlodipine requires immediate discontinuation of the drug and inpatient monitoring for cardiac arrhythmia — DHP CCBs are contraindicated once any orthostatic drop is detected regardless of symptom severity
• D) Uptitrate amlodipine to 5 mg immediately — the 16 mmHg systolic drop is within normal range; older adults physiologically have greater orthostatic BP variability and the threshold for clinical significance is 25 mmHg systolic in patients over 75; the BP improvement outweighs the modest positional change
• E) Switch from amlodipine to metoprolol succinate 25 mg — beta-blockers are specifically recommended when orthostatic hypotension develops on a CCB in elderly patients; the negative chronotropy of beta-blockade prevents the reflex tachycardia that accompanies orthostasis and reduces fall risk

15. [CASE 4 — QUESTION 15] At the 2-week recheck, orthostatic dizziness has improved with positional change counseling. Orthostatic BP drop is now 8 mmHg systolic (asymptomatic). Amlodipine is uptitrated to 5 mg. Four weeks later, BP is 150/62 mmHg — further improved but systolic still above target (below 150 mmHg per some very elderly guidelines, though below 130/80 mmHg per ACC/AHA 2017). Her physician considers adding a thiazide-type diuretic. Which of the following most accurately evaluates the addition of a thiazide-type diuretic in this specific patient?

• A) Indapamide SR 1.5 mg is contraindicated in patients over 75 — the HYVET trial demonstrated that indapamide causes severe hyponatremia in patients over 80, and extrapolation suggests the same risk at age 77; chlorthalidone should be used instead if a thiazide is needed
• B) Adding chlorthalidone 25 mg daily is the correct step — maximum doses of diuretics should be used from initiation in elderly patients with ISH because lower doses are ineffective; starting at 25 mg eliminates the need for subsequent uptitration visits
• C) Adding low-dose indapamide 1.25 mg or chlorthalidone 12.5 mg is appropriate — the HYVET trial used indapamide SR 1.5 mg as its primary agent (with optional add-on perindopril 2–4 mg) and demonstrated significant reductions in stroke, heart failure, and all-cause mortality in patients aged 80 and above; the combination of CCB plus thiazide-type diuretic provides complementary mechanisms (direct vasodilation plus volume reduction) and is evidence-aligned; starting at the lowest available dose reduces the risk of electrolyte disturbance (hyponatremia, hypokalemia — both more common in the elderly) and orthostatic hypotension; electrolytes and creatinine should be rechecked within 2–4 weeks of initiation
• D) No thiazide should be added — U.P.'s systolic BP of 150 mmHg meets the guideline target of below 150 mmHg for patients over 80; further reduction risks the J-curve harm; current treatment should be maintained without escalation
• E) Adding spironolactone 25 mg is preferred over a thiazide in an elderly patient — PATHWAY-2 evidence supports spironolactone as the most effective diuretic addition for any hypertensive patient with suppressed renin; elderly patients have universally suppressed PRA and therefore respond best to MRA therapy

16. [CASE 4 — QUESTION 16] Indapamide 1.25 mg daily is added. At 6 weeks, BP is 138/60 mmHg. Potassium is 3.6 mEq/L (mildly low) and sodium is 138 mEq/L. Creatinine is stable. Diastolic BP of 60 mmHg concerns the cardiologist covering for U.P.'s physician, who considers reducing the antihypertensive regimen. Which of the following most accurately evaluates the clinical significance of the diastolic BP of 60 mmHg in this patient and the appropriate management?

• A) The diastolic BP of 60 mmHg is an emergency — a diastolic below 65 mmHg in an elderly patient always indicates impending cardiovascular collapse; all antihypertensives should be immediately discontinued and the patient observed in a monitored setting
• B) The diastolic BP of 60 mmHg confirms J-curve coronary harm — U.P. is experiencing subclinical coronary hypoperfusion; the indapamide should be discontinued immediately and amlodipine reduced to 2.5 mg regardless of the effect on systolic BP control
• C) The low potassium of 3.6 mEq/L is the primary concern — indapamide is causing hypokalemia that is directly causing the low diastolic BP through vasodilation from intracellular potassium depletion; potassium supplementation alone will restore the diastolic to normal without any medication changes
• D) The diastolic BP of 60 mmHg warrants careful clinical assessment but not automatic antihypertensive reduction — the J-curve phenomenon (harm from excessive diastolic lowering) is most robustly established in patients with established coronary artery disease (where coronary perfusion occurs predominantly during diastole); U.P. has no history of CAD; in patients without established CAD, diastolic BP below 70 mmHg is not associated with the same degree of coronary harm; the systolic BP of 138 mmHg represents meaningful cardiovascular risk reduction; the appropriate response is clinical assessment for symptoms (chest pain, dizziness, fatigue), current home BP trends, and orthostatic measurements — not reflexive dose reduction based solely on the office diastolic reading
• E) The diastolic BP of 60 mmHg with potassium 3.6 mEq/L requires a balanced clinical response: the diastolic drop reflects primarily the indapamide's natriuretic and mild vasodilatory effect in an elderly patient with naturally low pulse pressure reserve; the J-curve risk at DBP 60 mmHg is most clinically relevant in established CAD — which U.P. does not have — and isolated diastolic reduction to 60 mmHg in an elderly ISH patient without CAD is less concerning than the same reading in a patient with obstructive coronary disease; however, the hypokalemia (3.6 mEq/L) should be addressed with dietary potassium encouragement or low-dose potassium supplementation; orthostatic BP should be remeasured; if she is symptom-free with no orthostatic drop and no symptoms of low cardiac output, the current regimen is appropriate to continue with close monitoring; the systolic reduction from 172 to 138 mmHg represents the primary therapeutic goal that outweighs the concern about modestly low diastolic in a non-CAD patient

17. [CASE 5 — QUESTION 17] V.J. is a 51-year-old man with hypertension on telmisartan 80 mg and amlodipine 10 mg daily. His home BP average is 142/90 mmHg — above target. His physician wants to add a third agent and considers chlorthalidone. Before prescribing, she reviews telmisartan's unique pharmacological properties and how they interact with the combination. Which of the following most accurately describes telmisartan's unique pharmacological properties beyond its AT1 receptor blockade, and whether they influence the choice of third agent?

• A) Telmisartan has the longest half-life among available ARBs (approximately 24 hours), providing the most complete 24-hour AT1 receptor blockade of any ARB — this is its primary unique property relevant to antihypertensive therapy; telmisartan also has partial PPARγ agonist activity (similar to the insulin-sensitizing thiazolidinediones) that may provide modest metabolic benefit including improved insulin sensitivity and favorable effects on lipid metabolism; telmisartan also demonstrated non-inferiority to ramipril (and better tolerability with less cough and angioedema) in ONTARGET for high-risk cardiovascular patients; these properties do not significantly influence the choice of third agent — chlorthalidone is pharmacologically appropriate as the volume-reducing complement to the existing RAAS inhibitor plus CCB combination regardless of which specific ARB is used
• B) Telmisartan is unique because it also inhibits ACE — it is a dual ARB-ACEi agent that provides both AT1 receptor blockade and bradykinin accumulation, explaining its superior antihypertensive efficacy; adding chlorthalidone to this dual inhibition creates dangerous triple RAAS blockade
• C) Telmisartan's PPARγ agonism means it raises serum potassium more than other ARBs through enhanced aldosterone suppression; adding chlorthalidone is contraindicated because the thiazide's potassium wasting will cause dangerous hypokalemia when suddenly opposing telmisartan's potassium-elevating effect
• D) Telmisartan is unique in that it must not be combined with diuretics — its 24-hour half-life makes it susceptible to profound first-dose hypotension when volume-depleted by a thiazide; all patients on telmisartan must be taken off the drug before a diuretic can be added
• E) Telmisartan's unique uricosuric properties through URAT1 inhibition specifically prevent diuretic-induced hyperuricemia — the combination of telmisartan plus chlorthalidone produces less hyperuricemia than any other ARB plus diuretic combination, making it the preferred pairing in patients at risk for gout

18. [CASE 5 — QUESTION 18] Chlorthalidone 12.5 mg daily is added. At 8 weeks, BP is 128/80 mmHg — at target. V.J. now asks his physician a question he encountered online: "I read that telmisartan blocks a receptor called AT2 as well as AT1 — is that right, and does it matter?" The physician wants to answer accurately. Which of the following most accurately describes telmisartan's (and all ARBs') receptor selectivity and the pharmacological significance of AT2 receptor activity?

• A) All ARBs including telmisartan block both AT1 and AT2 receptors — the combined blockade provides superior cardiovascular protection compared to ACEi (which only block AT2 receptors indirectly through reduced angiotensin II synthesis); this explains why ARBs are preferred over ACEi in high-risk patients
• B) Telmisartan uniquely blocks AT2 receptors in addition to AT1 receptors — this dual blockade is why telmisartan has superior antihypertensive efficacy compared to other ARBs that only block AT1; the AT2 blockade prevents the vasodilatory effect of AT2 receptor stimulation, providing additional vasoconstriction blockade
• C) ARBs including telmisartan selectively block AT1 receptors while sparing AT2 receptors — AT1 receptor stimulation mediates the harmful effects of angiotensin II (vasoconstriction, aldosterone secretion, inflammation, cellular hypertrophy); AT2 receptor stimulation generally opposes these effects (vasodilation, anti-proliferative, natriuretic); by blocking AT1 while sparing AT2, ARBs allow accumulated angiotensin II (from blocked AT1-mediated feedback suppression) to stimulate AT2 receptors — potentially providing additional vasodilatory and cardioprotective benefit; this receptor selectivity is a pharmacological advantage of ARBs over ACEi (which reduce angiotensin II synthesis and therefore do not drive AT2 stimulation)
• D) ARBs selectively block the AT1 receptor while leaving the AT2 receptor unblocked — when AT1 receptors are blocked by an ARB, the negative feedback suppression of renin is reduced (because AT1-mediated renin suppression is removed), leading to compensatory elevation of plasma angiotensin II; this elevated angiotensin II can then stimulate unblocked AT2 receptors; AT2 receptor stimulation produces effects generally considered beneficial (vasodilation, bradykinin release, anti-fibrotic signaling) — this unopposed AT2 stimulation is a proposed pharmacological advantage of ARBs, though the clinical significance of this mechanism in humans remains an area of ongoing research
• E) The AT2 receptor does not exist — angiotensin II has only one receptor subtype (AT1); the online information V.J. read is inaccurate; all ARBs block the single angiotensin II receptor completely; there is no additional receptor pharmacology to consider

19. [CASE 5 — QUESTION 19] V.J. has been on telmisartan 80 mg, amlodipine 10 mg, and chlorthalidone 12.5 mg for 18 months with excellent control (home BP average 126/80 mmHg). He is now 53 years old. At a routine visit, he mentions he has been taking ibuprofen 400 mg twice daily for 3 weeks for low back pain, prescribed by an urgent care physician who was unaware of his antihypertensive regimen. His home BP over the past 3 weeks has risen to an average of 142/88 mmHg. His physician reviews the interaction. Which of the following most accurately explains the mechanism of the BP rise and the correct action?

• A) Ibuprofen interacts with amlodipine through CYP3A4 induction — ibuprofen induces hepatic CYP3A4, accelerating amlodipine metabolism and reducing its plasma levels by approximately 40%; the BP rise reflects loss of CCB efficacy; the solution is to add a second CCB while continuing ibuprofen
• B) Ibuprofen interacts specifically with telmisartan through competition at the ARB binding site — NSAIDs and ARBs share a common pharmacophore that competes for AT1 receptor binding; ibuprofen's higher affinity displaces telmisartan from the AT1 receptor, abolishing RAAS inhibition
• C) Ibuprofen causes the BP rise through peripheral alpha-1 receptor stimulation — all NSAIDs stimulate adrenergic receptors through their prostaglandin E2 pathway effects on the sympathetic ganglion; the resulting vasoconstriction is antagonized by stopping the NSAID
• D) The BP rise is a nocebo effect — patients on antihypertensives who are told their medication might not work due to a drug interaction will physiologically raise their BP through anxiety-mediated sympathetic activation; no pharmacological intervention is needed
• E) Ibuprofen inhibits renal COX enzymes, reducing prostaglandin E2 and prostacyclin — these prostaglandins normally promote sodium excretion and vasodilation; their suppression causes sodium and water retention (opposing the antihypertensive effect of chlorthalidone), afferent arteriolar vasoconstriction (reducing the efficacy of telmisartan's efferent arteriolar dilation), and direct blunting of the antihypertensive mechanisms of all three agents by an average of 3–5 mmHg; the triple whammy of NSAID plus ARB plus diuretic also significantly elevates AKI risk; the correct action is to discontinue ibuprofen immediately, substitute acetaminophen for pain management, recheck BP in 2 weeks (expecting return to baseline as prostaglandin synthesis recovers), and check creatinine and potassium given the triple whammy AKI risk during the NSAID exposure period

20. [CASE 5 — QUESTION 20] Ibuprofen is discontinued and acetaminophen is substituted. At 2-week recheck, BP is 128/82 mmHg — back to baseline. Creatinine is 1.0 mg/dL (unchanged), potassium 4.3 mEq/L — no evidence of AKI from the triple whammy exposure. V.J. asks whether he can ever use ibuprofen again for acute pain in the future, or whether it is permanently contraindicated. Which of the following most accurately addresses this question?

• A) Ibuprofen is permanently contraindicated in all patients on ARBs or diuretics — the triple whammy combination always causes AKI regardless of duration or dose; V.J. must avoid all NSAIDs permanently for the rest of his life
• B) Ibuprofen can be used freely at any dose for any duration without concern for patients whose creatinine is normal at baseline — the AKI risk only applies to patients with pre-existing CKD; V.J. can use it without restrictions
• C) NSAIDs including ibuprofen should be avoided when possible given the interactions with his antihypertensive regimen; however, brief courses (3–5 days) of the lowest effective NSAID dose may be acceptable for acute pain management when acetaminophen is inadequate — with the understanding that BP will likely rise modestly during the course and should be monitored, and that creatinine and potassium should be checked if the course exceeds 5–7 days; the patient should notify his prescribing physician before starting any NSAID to allow assessment; for ongoing musculoskeletal pain, topical NSAIDs (diclofenac gel) provide local anti-inflammatory benefit with substantially less systemic prostaglandin suppression and far less BP and renal impact — a useful alternative for localized pain
• D) Ibuprofen is contraindicated only if combined with chlorthalidone — the triple whammy risk is eliminated by switching the diuretic to an MRA (spironolactone) before any future NSAID use; spironolactone's mechanism does not involve tubular sodium transport and therefore avoids the triple whammy
• E) V.J. can use ibuprofen freely because the BP interaction is not reproducible — the 16 mmHg systolic rise was within normal day-to-day BP variability and cannot be attributed to ibuprofen with certainty; single drug interactions cannot be established from one clinical observation

21. [CASE 6 — QUESTION 21] W.B. is a 66-year-old man with hypertension who presents to the ED with BP 192/114 mmHg. He reports his "blood pressure pills ran out 5 days ago." He takes lisinopril 40 mg and amlodipine 10 mg. He has no symptoms — no headache, no chest pain, no dyspnea, no visual changes. Neurological exam is normal. ECG shows LVH by voltage criteria only. Troponin is undetectable. Urinalysis is normal. Which of the following most accurately classifies this presentation and identifies the correct management?

• A) This is hypertensive emergency — BP of 192/114 mmHg always requires IV antihypertensive therapy and ICU admission; the absence of symptoms does not change the requirement for IV treatment above 180/120 mmHg
• B) This is hypertensive urgency requiring hospital admission — BP above 180/120 mmHg without target organ damage is still dangerous and requires at least 24 hours of inpatient monitoring before any oral antihypertensives are initiated; discharging from the ED with oral agents is unsafe
• C) This is hypertensive urgency — BP above 180/120 mmHg without evidence of acute target organ damage; a review of all available evidence reveals no papilledema, no focal neurological signs, no chest pain, no ECG ischemia, no troponin elevation, no acute renal injury, and no pulmonary edema; LVH on ECG represents chronic adaptation, not acute damage; the appropriate management is oral antihypertensive therapy with the goal of BP reduction over 24–48 hours, not within minutes; he can be restarted on his prescribed lisinopril and amlodipine at their usual doses with close outpatient follow-up arranged within 24–72 hours; medication refill should be facilitated; counseling on uninterrupted medication supply is essential
• D) This is a new diagnosis of hypertension requiring full secondary cause workup before any pharmacological treatment — since his medications ran out 5 days ago, his current BP may represent his true untreated BP; all antihypertensives should be withheld pending workup
• E) This is hypertensive urgency — BP above 180/120 mmHg without evidence of acute target organ damage; restarting his lisinopril and amlodipine at their prescribed doses is the most pharmacologically rational management — these are the agents his BP was previously controlled on; the mechanism of the elevated BP is medication discontinuation, not a change in underlying pathophysiology requiring different drugs; an additional oral agent for faster acute effect in the ED setting (such as captopril 25 mg or oral clonidine 0.2 mg) can be considered for the initial visit if BP is very concerning to the treating clinician, but is not mandatory; close follow-up within 24–72 hours to confirm return to controlled BP, with prescription facilitation to prevent future gaps

22. [CASE 6 — QUESTION 22] W.B.'s medications are restarted. At 48-hour follow-up, BP is 148/90 mmHg — improved but still elevated. At 2-week follow-up, BP is 136/84 mmHg — approaching but not quite at target. His physician is satisfied with the trajectory but reviews why BP control was suboptimal even before the medication gap. She notes his clinic records show BP averaging 138–142/86–90 mmHg over the past year, suggesting borderline control. She considers whether the patient's adherence pattern during the year may have been inconsistently incomplete — taking medications on most but not all days. She orders urine drug levels, which reveal low-therapeutic amlodipine and absent lisinopril metabolites collected on a clinic visit day. Which of the following most accurately addresses this adherence finding and its implications?

• A) The urine drug levels confirm that W.B. is never taking his medications — the absent lisinopril metabolites prove complete non-adherence; all medications should be re-initiated as if newly prescribed with intensive pharmacy monitoring
• B) The urine drug level findings — absent lisinopril metabolites and low-therapeutic amlodipine on a clinic visit day — are consistent with inconsistent adherence or the "white coat effect" of taking medications specifically before clinic appointments but missing them on other days; this pattern produces near-normal BP on clinic days (where compliance was highest) with elevated home BP on days when doses are missed; the appropriate response is shared decision-making to identify adherence barriers (cost, side effects, pill burden, forgetfulness), simplification of the regimen through a single-pill combination (lisinopril/amlodipine SPC if available), pill organizers or phone reminders, and closer monitoring — not interpretation of a single urine drug level as proof of complete non-adherence requiring a restart
• C) The urine drug levels are invalid because amlodipine's 30–50 hour half-life means it accumulates in plasma and cannot be used as an adherence biomarker — plasma levels are always detectable regardless of adherence; only short-acting drugs can be meaningfully assessed by urine drug levels
• D) The urine drug level findings prove that both drugs need to be switched — inconsistent adherence to a twice-daily regimen indicates that once-daily agents are needed; lisinopril and amlodipine should be replaced with drugs requiring less frequent dosing
• E) The urine drug levels indicate malabsorption syndrome — both lisinopril and amlodipine are absorbed in the small intestine and undetectable/low levels indicate a GI absorption disorder; the patient should be referred to gastroenterology before any medication changes are made

23. [CASE 6 — QUESTION 23] After a shared decision-making conversation, W.B. reports that cost has been a barrier — he has a high-deductible insurance plan and has been rationing his medications during the months before his deductible resets. His physician transitions him to a generic single-pill combination of lisinopril 40 mg / amlodipine 10 mg (available and inexpensive as a generic). At 3-month follow-up, W.B. is consistently adherent (urine drug levels confirm both agents present at therapeutic levels) and BP is 132/82 mmHg. His physician now considers whether a third agent should be added to optimize BP control, or whether 132/82 mmHg on the dual regimen is at target and no further medication is needed. Which of the following most accurately determines whether W.B.'s current BP represents adequate target and whether a third agent is warranted?

• A) A BP of 132/82 mmHg is above the target of 120/75 mmHg recommended by the SPRINT trial for all patients with cardiovascular risk; a third agent should be added to achieve the SPRINT intensive target
• B) A BP of 132/82 mmHg is exactly at the ACC/AHA 2017 target of below 130/80 mmHg — no third agent is needed; the current dual regimen provides optimal evidence-based control
• C) Whether to add a third agent depends on W.B.'s specific cardiovascular risk profile and whether the current BP meets his individualized target — ACC/AHA 2017 recommends below 130/80 mmHg for patients with ASCVD risk ≥10% or established CVD/CKD/diabetes; if W.B. falls into a high-risk group, his current BP of 132/82 mmHg is above target (the target is below 130/80 mmHg, not below 132/82 mmHg); if he is lower risk (Stage 1 hypertension, ASCVD <10%), below 140/90 mmHg was the prior standard; the physician should calculate or reassess his current ASCVD risk to determine the appropriate target and whether the marginal difference (132 vs. target of 130 mmHg) warrants adding a third agent, given the cost, complexity, and adherence challenges already demonstrated
• D) A BP of 132/82 mmHg is at the individualized target of below 130/80 mmHg per ACC/AHA 2017 for his age and risk profile — the current dual regimen should be continued and optimized without adding a third agent unless BP rises above target; the priority is sustaining adherence to the current two-drug regimen, which has already demonstrated the difficulty of maintaining consistent adherence in this patient; adding a third agent increases pill burden and adherence complexity at a stage where BP is at target; reassess in 3–6 months with home BP monitoring to confirm sustained control
• E) The SPRINT trial demonstrated that all patients should target below 120 mmHg systolic — W.B.'s BP of 132 mmHg systolic represents inadequate control; two additional agents should be added immediately to achieve the intensive SPRINT target

24. [CASE 6 — QUESTION 24] W.B.'s physician decides to continue the dual SPC and monitor. At 6-month follow-up with home BP monitoring, his average home BP is 136/86 mmHg — slightly above the 130/80 mmHg target. He reports the SPC is affordable and he is taking it consistently. His ASCVD risk is recalculated: 14% (increased from prior calculation due to age progression). Given the 14% risk and the borderline BP, his physician now decides to add chlorthalidone 12.5 mg as a third agent. At 6-week follow-up after adding chlorthalidone, home BP is 128/80 mmHg — at target. Potassium is 3.7 mEq/L. Creatinine is stable. His physician considers whether a triple SPC (lisinopril/amlodipine/chlorthalidone-equivalent) would be preferable to maintaining the dual SPC plus separate chlorthalidone. Which of the following most accurately evaluates the clinical considerations for using a triple SPC versus a dual SPC plus separate diuretic in this patient?

• A) A triple SPC should be pursued whenever available and clinically appropriate — the adherence benefit of consolidating three agents into one pill is well-established (20–30% improvement over separate pills); for W.B., who has a documented history of adherence failure when pill burden increases, simplifying from two pills (dual SPC plus separate chlorthalidone) to one pill (triple SPC if available) addresses his specific adherence vulnerability; the key practical consideration is availability — triple SPCs containing an RAAS inhibitor, CCB, and thiazide are available in some formulations (e.g., perindopril/amlodipine/indapamide) but may not include the exact doses he requires; if a suitable triple SPC is available and affordable, the switch is pharmacologically sound
• B) A triple SPC is always inferior to separate pills because fixed-dose combinations prevent individualized dose titration — since W.B. required multiple dose adjustments to find his current doses, any SPC is inappropriate and he should use three separate pills
• C) Triple SPCs are not approved for use in the United States and are not part of current ACC/AHA guidelines — this treatment modality is only available in Europe and is not recommended for routine antihypertensive management in American patients
• D) The current dual SPC plus separate chlorthalidone should be maintained indefinitely — once a stable three-drug regimen is established, any formulation change risks destabilizing BP control through pharmacokinetic differences between formulations; the switch to a triple SPC is not clinically justified when the current regimen is working
• E) The triple SPC should only be used if W.B.'s insurance covers it at lower cost than two separate prescriptions — adherence benefit of triple SPC is only demonstrated in countries with national formulary systems where cost differences are controlled; in the US private insurance market, SPCs may cost more than generic separate pills, negating the adherence benefit

25. [CASE 7 — QUESTION 25] X.L. is a 54-year-old woman presenting to the emergency department with a 2-hour history of severe tearing chest pain radiating to the back, BP 216/128 mmHg in the right arm and 188/108 mmHg in the left arm (28 mmHg systolic differential), and heart rate 114 bpm. CT angiography confirms type A aortic dissection involving the ascending aorta, aortic arch, and proximal descending aorta. She has no prior history of hypertension or cardiovascular disease. The cardiac surgery team is mobilized for emergent repair. The attending anesthesiologist asks for guidance on preoperative pharmacological BP and heart rate management. Which of the following most accurately describes the correct preoperative pharmacological management and the physiological rationale?

• A) Start IV hydralazine 10 mg immediately — hydralazine provides rapid BP reduction without affecting heart rate; its selective arteriolar dilation is ideal for aortic dissection because it reduces pulse pressure (systolic minus diastolic), which is the primary mechanical driver of dissection propagation
• B) Start IV nicardipine infusion at 5 mg/hr, titrated to systolic BP below 140 mmHg — the DHP CCB provides smooth titratable BP reduction without the cardiac depression that beta-blockers cause in aortic surgery patients; calcium channel blockade is the preferred mechanism for aortic dissection because it prevents the coronary vasospasm that often complicates the perioperative period
• C) Start IV esmolol 500 mcg/kg bolus then 50–200 mcg/kg/min infusion to achieve heart rate below 60 bpm — this is the first priority to reduce dP/dt (the rate of aortic pressure rise); once heart rate control is established, add IV nicardipine or nitroprusside if systolic BP remains above 120 mmHg; the physiological rationale is that vasodilators given before beta-blockade cause reflex tachycardia that increases dP/dt and worsens shear stress on the dissected aortic wall — beta-blocker first ensures that any subsequent vasodilator cannot drive tachycardia through baroreceptor activation
• D) Start IV labetalol 20 mg bolus, repeat to total 300 mg — IV labetalol is first-line for type A dissection because its combined alpha-1 and beta-1 blockade provides simultaneous BP and heart rate reduction in a single agent; esmolol and nitroprusside are not needed when labetalol is used
• E) No pharmacological treatment is needed preoperatively — the cardiac surgery team will manage hemodynamics intraoperatively; preoperative antihypertensives risk causing hypotension that compromises coronary and cerebral perfusion before the patient reaches the operating room

26. [CASE 7 — QUESTION 26] Esmolol infusion achieves heart rate of 56 bpm within 12 minutes. Systolic BP remains 192 mmHg. IV nicardipine infusion is added and titrated. Systolic BP reaches 108 mmHg over the next 20 minutes (total MAP reduction approximately 29% from 157 mmHg at presentation to 112 mmHg). X.L. undergoes emergent type A aortic repair. The operation is successful. Postoperatively, she is extubated on day 2 and transferred out of ICU on day 4. The cardiology team now plans her long-term antihypertensive regimen. In the context of prior aortic dissection, which of the following most accurately identifies the pharmacological targets and preferred agents for long-term management?

• A) No long-term antihypertensives are needed — the aortic repair has eliminated the structural risk; X.L.'s hypertension before the dissection was stress-related; once she recovers from surgery, her BP will normalize and pharmacotherapy is unnecessary
• B) Long-term antihypertensives are needed but the target is the same as for uncomplicated hypertension (below 140/90 mmHg); any combination of antihypertensives is appropriate — there is no class preference for post-dissection patients
• C) Beta-blockers are specifically contraindicated long-term after aortic dissection because chronic beta-blockade causes aortic wall remodeling that weakens the repair; an ARB plus CCB combination should be used instead
• D) Long-term antihypertensives with aggressive targets are indicated — the target systolic BP after aortic dissection is typically below 120 mmHg; the preferred agents are beta-blockers (to maintain low dP/dt long-term) and additional antihypertensives as needed; the rationale is that the dissected and repaired aorta remains vulnerable to further propagation, redissection, and aneurysm formation — aggressive BP and heart rate control reduces these long-term risks
• E) Long-term antihypertensives are mandatory after aortic dissection with the target systolic BP of 120–130 mmHg or lower — beta-blockers are the cornerstone of long-term post-dissection management because they reduce both BP and dP/dt (aortic wall shear stress with each heartbeat), addressing the primary long-term risk of aneurysm formation, redissection, or extension; ARBs (particularly losartan, which may have additional anti-fibrotic effects on aortic connective tissue in patients with Marfan syndrome through TGF-&beta; pathway inhibition) are also appropriate as part of the antihypertensive regimen; a CCB (amlodipine) or thiazide can be added for additional BP control; the goal is the lowest BP the patient can tolerate without symptoms

27. [CASE 7 — QUESTION 27] X.L. is discharged on metoprolol succinate 50 mg daily and amlodipine 5 mg daily. At 6-week follow-up, BP is 134/82 mmHg and heart rate is 62 bpm. She tolerates the regimen well. Her cardiologist plans to optimize the regimen to achieve a systolic target below 130 mmHg and considers the addition of a RAAS inhibitor. Which of the following most accurately identifies whether an ACEi or ARB should be added, and which provides a pharmacological advantage in the post-dissection setting?

• A) An ARB (losartan, valsartan, or irbesartan) is pharmacologically preferred over an ACEi as the RAAS inhibitor in post-dissection management — both provide equivalent antihypertensive benefit, but ARBs additionally avoid the risk of ACEi-associated cough (which can create Valsalva-like hemodynamic stress on the aortic repair during coughing episodes, transiently raising intrathoracic pressure and aortic wall stress); in patients with Marfan syndrome specifically, losartan has demonstrated reduction in aortic root dilation rate through TGF-&beta; inhibition — a property not shared by ACEi; for X.L. (no Marfan syndrome), either agent is antihypertensively appropriate, but avoiding cough-related hemodynamic stress on the aortic repair supports ARB preference; the combination of beta-blocker plus ARB plus CCB addresses multiple vascular mechanisms and supports the 120–130 mmHg target
• B) An ACEi is strongly preferred over an ARB post-dissection — ACEi specifically inhibit aortic matrix metalloprotease-9 (MMP-9) activity through bradykinin accumulation, preventing progressive aortic extracellular matrix degradation; ARBs do not have this MMP-9 inhibitory mechanism and are pharmacologically inferior for aortic protection
• C) Neither ACEi nor ARB should be added — the beta-blocker plus CCB combination is the maximum recommended regimen for post-dissection patients; adding a third agent is not supported by any post-dissection guideline and risks hypotension that could impair the aortic repair anastomosis
• D) The choice between ACEi and ARB does not matter — they are pharmacologically identical at the clinical level for antihypertensive management; flip a coin and proceed with either
• E) An ACEi is preferred over an ARB post-dissection because ACEi cause bradykinin accumulation that directly stabilizes collagen crosslinks in the aortic wall — ACEi-associated bradykinin is deposited in the aortic media and provides structural reinforcement that prevents aneurysm formation; ARBs do not accumulate bradykinin and therefore lack this structural protection

28. [CASE 7 — QUESTION 28] Losartan 50 mg daily is added. At 3-month follow-up, BP is 126/78 mmHg — at target. Heart rate is 58 bpm. The regimen (metoprolol succinate 50 mg, amlodipine 5 mg, losartan 50 mg) is well tolerated. X.L. asks how long she will need to stay on these medications and whether the aortic repair means she is "cured" of her hypertension risk. Which of the following most accurately addresses her questions regarding the permanence of her antihypertensive therapy and her residual risk?

• A) X.L. has been cured of her hypertension risk by the aortic repair — surgical correction of the structural abnormality eliminates the hemodynamic stress that drove the dissection; her antihypertensives can be tapered over 6 months and discontinued once BP remains below 140/90 mmHg without medication
• B) X.L. requires lifelong antihypertensive therapy — the aortic repair treated the acute structural catastrophe but did not cure the underlying arterial pathophysiology driving her hypertension; the repaired and native aorta remains vulnerable to aneurysm dilation, redissection, and extension of any residual type B dissection in the descending aorta; lifelong aggressive BP control (target systolic 120–130 mmHg) and dP/dt reduction through beta-blockade are the primary modifiable determinants of long-term aortic outcomes; surveillance imaging (CT or MR angiography) at regular intervals (annually or as directed by her surgical team) is also required to monitor for aneurysmal change; her antihypertensives should not be discontinued
• C) X.L. only needs antihypertensives for 5 years post-dissection — once the aortic repair has fully healed and fibrosed (typically complete by 5 years), the structural risk is eliminated and pharmacological support is no longer needed; discontinuation of antihypertensives at the 5-year mark is guideline-endorsed
• D) X.L. can stop beta-blockers after 1 year — the beta-blocker is needed only during the acute healing phase of the aortic repair; once the anastomosis is fully healed, dP/dt control is no longer needed and the beta-blocker adds no further benefit; the ARB and CCB can be continued long-term for BP control
• E) X.L. should be told that the risk of redissection is now zero — modern surgical techniques for type A dissection achieve a durable cure; the 5-year freedom from reoperation rate exceeds 90%; her remaining antihypertensives are for blood pressure management unrelated to the dissection history; she can pursue any level of physical activity including high-intensity exercise without restriction